Mesco Pharmaceuticals Peer Comparison
NSE: MESCOPHARM | BSE: 500274
₹4.54
As on 10-Jan-2022IST
Market cap
₹9 Cr
Revenue (TTM)
₹0 Cr
P/E Ratio
--
P/B Ratio
-0.9
Div. Yield
0 %
| Mesco Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
9 | 32,104 | 29,892 | 29,103 | 26,871 |
Revenue (₹ Cr) |
-- | 3,564 | 1,936 | 9,205 | 1,462 |
Net Profit (₹ Cr) |
-0.01 | 414.00 | 288.22 | -371.81 | 387.35 |
Net Margin (%) |
-- | 11.23 | 14.79 | -3.93 | 26.01 |
RoE (%) |
-- | 8.38 | 29.77 | -3.85 | 25.18 |
Price to Earnings |
-- | 78.49 | 103.71 | -- | 69.57 |
Price-To-Book |
-0.88 | 6.38 | 22.27 | 3.64 | 15.55 |
Income Statement (₹ Cr)
| Mesco Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Operating Revenue
|
-- | 2,708.00 | 314.72 | 6,314.90 | 340.61 |
|
Total Income
|
0.00 | 2,840.00 | 324.85 | 6,479.01 | 341.99 |
|
Total Expenditure
|
0.00 | 2,771.00 | 223.05 | 4,886.94 | 260.45 |
|
EBITDA
|
0.00 | -63.00 | 91.67 | 1,427.96 | 80.15 |
|
Depreciation
|
-- | 246.00 | 29.31 | 545.04 | 4.19 |
|
EBIT
|
0.00 | -309.00 | 62.36 | 882.92 | 75.96 |
|
Interest
|
0.00 | 249.00 | 9.37 | 163.45 | 5.62 |
|
Other Income
|
-- | 132.00 | 10.13 | 164.11 | 1.38 |
|
Exceptional Items
|
-- | -142.00 | -- | 18.23 | -- |
|
Profit before Tax
|
0.00 | -568.00 | 63.12 | 949.05 | 71.73 |
|
Provision for Tax
|
-- | -271.00 | 32.43 | 114.02 | 17.73 |
|
Profit after Tax
|
0.00 | -297.00 | 30.69 | 835.03 | 54.00 |
Liabilities (₹ Cr)
| Mesco Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-11.02 | 3,376.00 | 374.15 | 5,605.00 | 166.93 |
|
Minority Interest
|
-- | 383.00 | 0.00 | -- | -- |
|
Non-Current Liabilities
|
11.18 | 496.00 | 52.94 | 2,560.38 | 80.29 |
|
Current Liabilities
|
0.02 | 3,121.00 | 111.16 | 2,590.70 | 166.04 |
|
Total Liabilities
|
0.18 | 7,746.00 | 538.25 | 10,777.71 | 413.27 |
Assets (₹ Cr)
| Mesco Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.18 | 4,951.00 | 201.99 | 7,006.96 | 190.83 |
|
Current Assets
|
0.00 | 2,281.00 | 336.26 | 3,749.12 | 216.23 |
|
Total Assets
|
0.18 | 7,746.00 | 538.25 | 10,777.71 | 413.27 |
|
Total Debt*
|
11.18 | 2,332.00 | 93.28 | 2,910.19 | 136.64 |
|
Net Current Assets
|
-0.01 | -840.00 | 225.10 | 1,158.42 | 50.19 |
|
Contingent Liabilities
|
-- | 639.00 | 30.36 | 29.98 | 0.00 |
Cashflow (₹ Cr)
| Mesco Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
0.00 | -287.00 | 56.87 | 597.58 | 27.96 |
|
Cash Flow from Investing Activities
|
-- | 1,470.00 | -36.45 | -4,479.93 | -101.21 |
|
Cash from Financing Activities
|
-0.03 | -1,171.00 | 52.49 | 3,976.83 | 72.11 |
|
Net Cash Inflow / Outflow
|
-0.04 | 12.00 | 72.91 | 94.48 | -1.14 |
Ratios
Profitability Ratios
| Mesco Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-2.08 | -5.50 | 17.30 | 13.06 | 33.43 |
|
ROE (%)
|
0.00 | -9.92 | 8.84 | 14.90 | 40.51 |
|
ROA (%)
|
-1.99 | -3.93 | 6.36 | 7.76 | 16.74 |
|
EBIT Margin (%)
|
-- | 2.55 | 32.35 | 25.21 | 23.94 |
|
Net Margin (%)
|
-- | -10.46 | 9.45 | 12.89 | 15.79 |
|
Cash Profit Margin (%)
|
-- | -1.10 | 19.06 | 19.71 | 17.08 |
Growth Ratios
| Mesco Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | -4.78 | 19.65 | 0.00 | 42.13 |
|
EBIT Growth (%)
|
96.07 | -56.28 | 3.17 | -- | 85.90 |
|
Net Profit Growth (%)
|
95.93 | -115.30 | -37.89 | 0.00 | 96.57 |
|
EPS Growth (%)
|
95.98 | 1,097.71 | -37.89 | 0.00 | -34.47 |
|
Book Value Growth (%)
|
-0.04 | 26.74 | 8.89 | 0.00 | 51.79 |
Valuation Ratios
| Mesco Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 6.12 | 0.00 | 0.00 | 0.00 |
|
Price / Book Value
|
0.00 | 1.36 | 0.00 | 0.00 | 0.00 |
|
Dividend Yield (%)
|
-- | 0.00 | -- | -- | -- |
|
EV/EBITDA
|
-7,999.21 | 95.62 | 0.14 | 2.20 | 2.03 |
|
Market Cap (₹ Cr)
|
-- | 4,557.85 | 0.00 | 0.00 | 0.00 |
Solvency Ratios
| Mesco Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-1.02 | 0.70 | 0.26 | 0.52 | 0.85 |
|
Short term debt to equity ratio
|
-- | 0.32 | 0.12 | 0.06 | 0.27 |
|
Current Ratio
|
0.18 | 0.73 | 3.02 | 1.45 | 1.30 |
|
Quick Ratio
|
0.18 | 0.47 | 2.46 | 0.97 | 0.94 |
|
Interest Coverage
|
-28.38 | -1.28 | 7.74 | 6.81 | 13.77 |
Operating Efficiency Ratios
| Mesco Pharmaceuticals | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 33.90 | 43.28 | 24.94 | 35.43 |
|
Asset Turnover
|
0.00 | 0.61 | 0.65 | 0.65 | 1.06 |
|
Receivable days
|
-- | 85.04 | 160.21 | 82.08 | 94.89 |
|
Inventory Days
|
-- | 59.63 | 58.00 | 64.21 | 60.39 |
|
Payable days
|
-- | 255.87 | 183.24 | 162.72 | 138.36 |
|
Cash Conversion Cycle
|
-- | -111.19 | 34.97 | -16.42 | 16.92 |